Clinical trials: Histological Response
MALIGNANT PLEURAL MESOTHELIOMA
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TSER polymorphism.
- Trial name
- NCT00867711
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- Istituto Clinico Humanitas
Glioblastoma
MET-PET for Newly Diagnosed Glioblastoma
This research study is a prospective pilot study. The purpose of a pilot clinical study is to obtain preliminary data to support the reason for doing a larger clinical trial on testing the clinical effectiveness of an…
- Trial name
- NCT01867593
- Testing
- C-11 methionine PET
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Melanoma, Non Small Cell Lung Cancer
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists
This is a prospective cohort study which aims to identify predictive factors of response to PD-1 and PD L1 antagonists authorised for use in France in treatment of melanoma, NSCLC, or HNSCC.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- CHECK'UP (NCT03412058)
- Testing
- Biopsy
- Where
- 19 sites in France
- Volunteers
- 152 people
- Sponsor
- UNICANCER
Retroperitoneal Sarcoma
The PET- Retroperitoneal Sarcoma Study
Retroperitoneal sarcoma(RPS) is a rare cancer that is difficult to cure as it typically presents as a very large abdominal mass, and complete removal with clear margins is challenging .
- Trial name
- PET-RPS (NCT04224948)
- Testing
- PET MRI scan
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- University Health Network, Toronto
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Breast Cancer
Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)
The general objective of the study is to improve the care of women with Human Epidermal Growth Factor Receptor-2 (HER2) positive metastatic or locally advanced breast cancer by using a radio-labelled biomarker with whole body…
- Trial name
- PETRA (NCT01805908)
- Testing
- 111In-Pertuzumab + SPECT-CT
- Where
- 2 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Malignant Melanoma Stage IV
Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI
Therapeutic agents used in malignant melanoma treatment such as BRAF/MEK inhibitors and anti-CTLA-4/Anti-PD-1 antibodies go along with harmful side effects in a considerable proportion of patients and treatment costs may cause…
- Trial name
- NCT03132090
- Testing
- PET/MR (Biograph mMR)
- Where
- Germany
- Volunteers
- 106 people
- Sponsor
- University Hospital Tuebingen
HRAS Gene Mutation, HNSCC
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN).
- Trial name
- AIM-HN/SEQ-HN (NCT03719690)
- Testing
- Tipifarnib, HRAS Detection Assay
- Where
- 102 sites in United States, Australia and 14 more
- Volunteers
- 296 people
- Sponsor
- Kura Oncology, Inc.
Lymphoma, Nonneoplastic Condition
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
- Trial name
- NCT01319526
- Testing
- DNA analysis, RNA analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- AIDS Malignancy Consortium
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Leukemia
Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop…
- Trial name
- NCT00066326
- Testing
- imatinib mesylate, tanespimycin
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Myeloma
A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment
This is an open-label, multicenter clinical trial designed to evaluate the safety and potential efficacy of venetoclax and ABBV-838 combination therapy with dexamethasone in participants with relapsed or refractory multiple…
- Trial name
- NCT02951117
- Testing
- Venetoclax, ABBV-838, Dexamethasone
- Where
- 3 sites in Australia
- Sponsor
- AbbVie
Solar Elastosis
Histologic Response to UVA and UVB Exposure During the Use of Sunscreen
Anti-inflammatory and anti-oxidant agents have become the important ingredients in sunscreen. However, there is no histologic study about the effects of anti-inflammatory and anti-oxidative properties of sunscreen to prevent…
- Trial name
- NCT01892150
- Testing
- Sunscreen
- Where
- Thailand
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Lymphoma, Lymphoma, B-Cell
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03696784
- Testing
- iC9-CAR19 T cells, Bendamustine, Fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
AL Amyloidosis
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
The goal of this clinical trial is to evaluate the effectiveness and safety of CM-336, which is a BCMA/CD3 BiTE, in patients with relapsed/refractory AL amyloidosis or newly diagnosed AL amyloidosis with insufficient depth of…
- Trial name
- NCT06769555
- Testing
- CM-336 BCMA/CD3 bispecific antibody
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lymphoma, Large-Cell
Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT
Patients affected with non-Hodgkin's large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is…
- Trial name
- NCT00256490
- Testing
- PET/CT 20 days after the first cycle of chemotherapy
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Eric Turcotte
Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma
Multiparametric Quantitative MRI and Response to Neoadjuvant Radiotherapy for Soft-tissue Sarcoma
This trial is a prospective, monocentric, with minimal risks and constraints study, conducted in patients with Soft Tissue Sarcoma (STS) of the limbs and trunk with indication for neoadjuvant radiotherapy (RT).
- Conditions
- Soft Tissue Sarcoma, Adult Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma
- Trial name
- SarQuantIRM (NCT05684874)
- Testing
- Neoadjuvant RT, Pre-radiotherapy mpMRI, Post-radiotherapy mpMRI
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Lymphoma, Multiple Myeloma
Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients
Primary objective 1) To assess whether oncologic and hematologic patients develop a protective immunological response after pandemic Influenza A (H1N1) vaccine Secondary objectives 1.
- Conditions
- Lymphoma, Multiple Myeloma, Myeloproliferative Disease
- Trial name
- NCT01394640
- Testing
- Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus
- Where
- Italy
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Paolo Corradini
Chronic Myeloid Leukemia
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Research Hypothesis: Treatment with dasatinib 100 mg QD is superior to imatinib 600 mg QD in terms of complete cytogenetic response (CCyR) in chronic phase (CP) Philadelphia chromosome-positive (Ph+) Chronic Myeloid Leukemia…
- Trial name
- NCT00854841
- Testing
- Dasatinib and Imatinib
- Sponsor
- Pusan National University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.